GSK 461364A

12/01/2020 - "The present study elucidated the potential cytotoxic effects of a PLK1 inhibitor, GSK461364A, in five cancer cell lines including Raji, K562, PC3, MCF-7, MDA-MB-231, along with noncancerous L929 cells by XTT assay. "
08/01/2023 - "Nevertheless, more research is needed to evaluate GSK461364A as a cancer treatment drug."
12/01/2011 - "GSK461364A sensitized tumor cells to radiation induced cell death in vitro. "
07/01/2010 - "Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability."
07/01/2010 - "As many cancer therapies tend to be more effective in p53 WT patients, the higher sensitivity of p53-deficient tumors toward GSK461364A could potentially offer an opportunity to treat tumors that are refractory to other chemotherapies as well as early line therapy for these genotypes."

10/01/2013 - "The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations."

12/01/2011 - "Using a breast cancer brain metastatic xenograft model (231-BR), we tested the efficacy of GSK461364A to prevent brain metastatic colonization. "

07/01/2010 - "Further mechanistic studies showed that p53 wild-type (WT) and not mutant cells can activate a postmitotic tetraploidy checkpoint and arrest at pseudo-G(1) state after GSK461364A treatment. "

08/01/2023 - "In this context, the aim of the present study was to evaluated the potential cytotoxic effects of GSK461364A, a competitive inhibitor for PLK1, in gastric cancer cell line SNU-1 cells and explored its cytotoxic mechanism. "
08/01/2023 - "Current findings suggest that GSK461364A may be a chemotherapeutic agent in patients with gastric cancer. "
08/01/2023 - "GSK461364A suppresses proliferation of gastric cancer cells and induces apoptosis."